Compare TIGO & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIGO | NBIX |
|---|---|---|
| Founded | 1990 | 1992 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 13.2B |
| IPO Year | 1997 | 1996 |
| Metric | TIGO | NBIX |
|---|---|---|
| Price | $98.60 | $171.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 22 |
| Target Price | $68.30 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $41.91 | $24.73 |
| Revenue Next Year | $4.06 | $13.14 |
| P/E Ratio | ★ $10.21 | $90.99 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $38.50 | $122.14 |
| 52 Week High | $98.94 | $181.18 |
| Indicator | TIGO | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 65.68 | 56.37 |
| Support Level | $81.93 | $153.96 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.15 | 4.81 |
| MACD | 0.55 | -0.05 |
| Stochastic Oscillator | 89.48 | 49.84 |
Millicom offers wireless and fixed-line telecom services primarily in smaller, less developed countries in Latin America. Countries served include Bolivia, Nicaragua, Panama, El Salvador, Guatemala, Paraguay, Colombia, Ecuador, Uruguay, and Honduras (67% but not controlled or consolidated in the firm's financial statements). The firm's wireless networks cover about 145 million people, serving nearly 60 million customers. Its fixed-line networks reach 22 million homes, serving about 5.6 million broadband customers. Increasingly, Millicom offers converged packages that include broadband with wireless services. The firm also formed a joint venture to acquire Telefónica's operations in Chile.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.